Evidence check: LCT in the context of menopause

The question about LCT (lactase gene) in the context of menopause primarily concerns calcium absorption and bone health. During menopause, estrogen decline increases osteoporosis risk. Reduced lactase activity (lactose intolerance) might impair calcium intake from dairy. However, evidence for a direct link between LCT variants and osteoporosis is moderate. Studies show lactose intolerance can reduce calcium absorption, but many individuals compensate via other calcium sources or adjusted diets. Bone density is influenced by multiple factors (exercise, vitamin D, genetics). A DNA test for LCT can indicate possible lactose intolerance but cannot provide personalized osteoporosis prevention. Clinical relevance is limited; bone density scans and calcium/vitamin D supplementation as needed are more evidence-based. Caveat: No randomized trials show that LCT-based diet improves menopause-related bone health. Evidence: human-moderate.